Seelos Therapeutics to Participate in the 33rd Annual Roth Conference

Seelos Therapeutics (Nasdaq: SEEL) will participate in the 33rd Annual Roth Conference virtually from March 15-17, 2021.

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) will participate in the 33rd Annual Roth Conference virtually from March 15-17, 2021. Chairman and CEO Raj Mehra, Ph.D., will conduct 1x1 meetings on March 16 and 17. The company focuses on developing therapies for central nervous system disorders and rare diseases, with a portfolio including treatments for conditions like Acute Suicidal Ideation in Major Depressive Disorder and Parkinson's disease. For more information, visit seelostherapeutics.com.

Argus Session date unavailable

-3.51% session move Open Argus

Details

News Market Reaction – SEEL

The recorded move for SEEL in the trading session of this news was -3.51%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 17, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 33^rd Annual Roth Conference, which will be held virtually on March 15-17, 2021.

Raj Mehra, Ph.D., Chairman and CEO, will host 1x1 meetings via conference calls on March 16^th and 17^th.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com 
https://seelostherapeutics.com/ 
https://twitter.com/seelostx 
https://www.linkedin.com/company/seelos

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-the-33rd-annual-roth-conference-301229245.html

SOURCE Seelos Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Seelos Therapeutics participating in the Roth Conference?

Seelos Therapeutics will participate in the Roth Conference from March 15-17, 2021.

Who will represent Seelos at the Roth Conference?

Raj Mehra, Ph.D., Chairman and CEO, will represent Seelos Therapeutics at the conference.

What is the focus of Seelos Therapeutics?

Seelos Therapeutics focuses on developing therapies for central nervous system disorders and rare diseases.

What diseases does Seelos Therapeutics target?

Seelos Therapeutics targets diseases such as Major Depressive Disorder, PTSD, ALS, and Sanfilippo syndrome.

How can I find more information about Seelos Therapeutics?

For more information about Seelos Therapeutics, visit their website at seelostherapeutics.com.